The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Open accessAbstract
The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a therapeutic context, however, the cytotoxic effector function of an antibody is often not desirable and can create safety liabilities by activating native host immune defenses against cells expressing the receptor antigens. Several amino acid changes in the Fc region have been reported to silence or reduce the effector function of antibodies. These earlier studies focused primarily on the interaction of human antibodies with human Fc-γ receptors, and it remains largely unknown how such changes to Fc might translate to the context of a murine antibody. We demonstrate that the commonly used N297G (NG) and D265A, N297G (DANG) variants that are efficacious in attenuating effector function in primates retain potent complement activation capacity in mice, leading to safety liabilities in murine studies. In contrast, we found an L234A, L235A, P329G (LALA-PG) variant that eliminates complement binding and fixation as well as Fc-γ-dependent, antibody-dependent, cell-mediated cytotoxity in both murine IgG2a and human IgG1. These LALA-PG substitutions allow a more accurate translation of results generated with an "effectorless" antibody between mice and primates. Further, we show that both human and murine antibodies containing the LALA-PG variant have typical pharmacokinetics in rodents and retain thermostability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to generating highly effector-attenuated bispecific antibodies for preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 1×
“The challenges in translating antibody properties from animals to humans have long been recognized and partially result from the protein sequence differences between human and murine antibodies (7).”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Self-citationBiopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Self-citationThe 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein
Vermeer, A. W. P., & Norde, W. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76602-1 · Cited by 666
FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Self-citationTao, M. H., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 530
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425 · cited 1×
“To identify effector silencing substitutions that could both improve the production of murine IgG2a-bispecific antibodies and effectively reduce effector function, we screened several antibody variants, including the recently identified combination of L234A, L235A, and P329A (LALA-PG) substitutions that have been show…”
BackgroundMapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Self-citationTherapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Self-citationMarketed therapeutic antibodies compendium
Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.19931 · Cited by 368
Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12161-12168.2001 · Cited by 294
Dangl, J. L., Wensel, T. G., Morrison, S. L., Stryer, L., Herzenberg, L. A., & Oi, V. T. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03037.x · Cited by 282
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 268
Self-citationEaton, D. L., Wood, W. I., Eaton, D., Hass, P. E., Hollingshead, P., Wion, K., Mather, J., Lawn, R. M., Vehar, G. A., & Gorman, C. (1986) · Biochemistry · doi:10.1021/bi00374a001 · Cited by 267
Complement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
Atwell, S., Ridgway, J. B. B., Wells, J. A., & Carter, P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1116 · Cited by 261
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236
Lund, J., Takahashi, N., Pound, J. D., Goodall, M., & Jefferis, R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4963 · Cited by 216
Spiess, C., Merchant, M., Huang, A., Zheng, Z., Yang, N.-Y., Peng, J., Ellerman, D., Shatz, W., Reilly, D., Yansura, D. G., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2621 · Cited by 197
Self-citationAglycosylated immunoglobulin G1variants productively engage activating Fc receptors
Sazinsky, S. L., Ott, R. G., Silver, N. W., Tidor, B., Ravetch, J. V., & Wittrup, K. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809257105 · Cited by 177
Chappel, M. S., Isenman, D. E., Everett, M., Xu, Y. Y., Dorrington, K. J., & Klein, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9036 · Cited by 131
Welfle, K., Misselwitz, R., Hausdorf, G., Höhne, W., & Welfle, H. (1999) · Biochimica et Biophysica Acta · doi:10.1016/s0167-4838(99)00046-1 · Cited by 111
Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110
Self-citationFc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer
Bakema, J. E., & van Egmond, M. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_17 · Cited by 99
Shatz-Binder, W., Chung, S., Li, B., Marshall, B., Tejada, M. L., Phung, W., Sandoval, W. N., Kelley, R. F., & Scheer, J. M. (2013) · mAbs · doi:10.4161/mabs.26307 · Cited by 94
Self-citationTherapeutic Monoclonal Antibodies
An, Z. (2009) · Wiley eBooks · doi:10.1002/9780470485408 · Cited by 90
Ernst, L. K., Metes, D., Herberman, R. B., & Morel, P. A. (2001) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0294-2 · Cited by 81
With or Without Sugar? (A)glycosylation of Therapeutic Antibodies
Hristodorov, D., Fischer, R., & Lindén, L. (2012) · Molecular Biotechnology · doi:10.1007/s12033-012-9612-x · Cited by 80
Arduin, E., Arora, S., Bamert, P. R., Kuiper, T., Popp, S. L., Geisse, S., Grau, R., Calzascia, T., Zenke, G., & Kovařík, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.017 · Cited by 79
Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1
Nesspor, T., Raju, T. S., Chin, C., Vafa, O., & Brezski, R. J. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2155 · Cited by 53
Self-citationWong, A. W., Baginski, T. K., & Reilly, D. E. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22749 · Cited by 46
Lu, Y., Vernes, J.-M., Chiang, N., Ou, Q., Ding, J., Adams, C. W., Hong, K., Truong, B.-T., Ng, D., Shen, A. Y., et al. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.12.014 · Cited by 31
Self-citation
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei, A. S., Ricci, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.013 · Cited by 656
“To generate recombinant antibody, the heavy chain gBlocks (VH and CH1 mIgG2A; Integrated DNA technologies) was cloned into the pFUSEmIgG2A-Fc1 vector with L234A, L235A, P329G (LALA-PG) mutation (Lo et al., 2017), and the light chain gBlock (VL and Cκ; Integrated DNA technologies) was cloned into the mIgG2Adeficient pF…”
Dejanovic, B., Huntley, M. A., De Mazière, A., Meilandt, W. J., Wu, T., Srinivasan, K., Jiang, Z., Gandham, V., Friedman, B. A., Ngu, H., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.014 · Cited by 517
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R., Totpal, K., Chiu, H., Wu, Y., Comps-Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 459
Zhou, Y., Fei, M., Zhang, G., Liang, W.-C., Lin, W., Wu, Y., Piskol, R., Ridgway, J., McNamara, E., Huang, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.014 · Cited by 399
Metadata
- Authors
- Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., Watts, R. J., Couch, J. A., Meng, Y. G., Atwal, J. K., Brezski, R. J., Spiess, C., & Ernst, J. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 292
- Issue
- 9
- Pages
- 3900-3908
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2578585563
- Cited by
- 323
- References
- 43
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.